EsoGuard(R) now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter
Conference call and webcast to be held today, November 12, at 8:30 AM EST
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update and reported financial results for the third quarter ended September 30, 2026.
Conference Call and Webcast
The webcast will take place on Thursday, November 12, 2026, at 8:30 AM EST and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days in the investor relations section of the Company's website at luciddx.com.
Business Highlights
"Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth."
"Our pursuit of EsoGuard's enormous clinical and commercial opportunity is now substantially less constrained by external factors," Dr. Aklog added. "Lucid's near-term growth now depends almost entirely on our team's commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint."
Highlights from the third quarter and recent weeks:
-- Received first Medicare payments for the EsoGuard(R) Esophageal DNA
Test in October. Lucid began submitting claims in late September after
meeting with medical directors at Novitas, the Medicare Administrative
Contractor (MAC) with jurisdiction over Lucid's Texas laboratory, and
providing a clinical evidence dossier incorporating their feedback. Lucid
has consistently received payments on these claims at EsoGuard's
established Clinical Laboratory Fee Schedule rate of $1,938.01 per test.
This Medicare coverage through claim-by-claim adjudication is independent
of the pending MolDX Local Coverage Determination (LCD) reconsideration
for EsoGuard.
-- Immediately and aggressively repositioned commercial efforts to expand
EsoGuard testing among at-risk Medicare beneficiaries, representing
approximately half of the patients recommended for esophageal precancer
testing by professional society guidelines.
-- Performed 2,871 EsoGuard tests and recognized revenue of $1.2 million in
3Q26. October was a record month for EsoGuard test volume, with more than
1,800 tests. More than 50,000 EsoGuard tests have been performed since
launch.
-- Held a formal meeting with CMS leadership on the pending MolDX LCD
reconsideration for EsoGuard. The discussion reinforced Lucid's
confidence that the delay is attributable to an administrative backlog.
Lucid expects the draft LCD to be published as that backlog begins to
clear.
-- Continued to expand commercial coverage through the Concert EsoGuard
coverage policy, with a total of five Concert client health plans,
including the three previously reported, expected to have formally
adopted it by year-end.
-- Launched Lucid's first two U.S. Department of Veterans Affairs
(VA) programs, with a robust pipeline of additional VA centers behind
them. Lucid continues to expect the VA to be a meaningful long-term
contributor to its commercial activity and revenue.
-- Announced billing and coding milestones, including a new Category III CPT
code for EsoCheck cell collection and a proposed ICD-10 diagnosis code
for positive EsoGuard results, which will make EsoGuard and EsoCheck
easier to bill, track and integrate into clinical practice.
-- Announced publication of an 11,991-patient real-world EsoGuard study, the
largest peer-reviewed study of nonendoscopic esophageal precancer testing
to date. Sampling with the EsoCheck(R) Esophageal Cell Collection
Device was successful in 95% of patients and averaged less than two
minutes. The procedure was well tolerated, with no reported
device-related adverse events and consistent performance across operators,
including newly trained personnel.
-- The American Gastroenterological Association (AGA) released its draft
Barrett's esophagus guidelines for public comment. The draft names
EsoGuard and EsoCheck as an alternative to endoscopy, with high certainty
of evidence. EsoGuard is the only commercially available test cited.
-- Strengthened balance sheet with a $15.0 million private placement to
existing long-term investors.
Financial Results
-- For the three months ended September 30, 2026, EsoGuard related revenues
were $1.2 million. Operating expenses were approximately $13.5 million,
which included stock-based compensation expenses of $1.5 million. GAAP
net loss attributable to common stockholders was approximately $6.7
million, or $(0.03) per common share.
-- As shown below and for the purpose of illustrating the effect of
stock-based compensation and other non-cash income and expenses on the
Company's financial results, the Company's non-GAAP adjusted loss for the
three months ended September 30, 2026 was approximately $10.6 million or
$(0.06) per common share.
-- Lucid had cash and cash equivalents of $18.0 million as of September 30,
2026, compared to $34.7 million as of December 31, 2025. Subsequent to
quarter end, Lucid closed a $15.0 million Series C Convertible Preferred
Stock financing.
-- The unaudited financial results for the three and nine months ended
September 30, 2026, were filed with the SEC on Form 10-Q on November 12,
2026, and available at www.luciddx.com or www.sec.gov.
Lucid Non-GAAP Measures
-- To supplement our unaudited financial results presented in accordance
with U.S. generally accepted accounting principles (GAAP), management
provides certain non-GAAP financial measures of the Company's financial
results. These non-GAAP financial measures include net loss before
interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP
adjusted loss, which further adjusts EBITDA for stock-based compensation
expense and other non-cash income and expenses, if any. The foregoing
non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not
recognized terms under U.S. GAAP.
-- Non-GAAP financial measures are presented with the intent of providing
greater transparency to the information used by us in our financial
performance analysis and operational decision-making. We believe these
non-GAAP financial measures provide meaningful information to assist
investors, shareholders, and other readers of our unaudited financial
statements in making comparisons to our historical financial results and
analyzing the underlying performance of our results of operations. These
non-GAAP financial measures are not intended to be, and should not be, a
substitute for, considered superior to, considered separately from, or as
an alternative to, the most directly comparable GAAP financial measures.
-- Non-GAAP financial measures are provided to enhance readers' overall
understanding of our current financial results and to provide further
information for comparative purposes. Management believes the non-GAAP
financial measures provide useful information to management and investors
by isolating certain expenses, gains, and losses that may not be
indicative of our core operating results and business outlook.
Specifically, the non-GAAP financial measures include non-GAAP adjusted
loss, and its presentation is intended to help the reader understand the
effect of the loss on the issuance or modification of convertible
securities, the periodic change in fair value of convertible securities,
the loss on debt extinguishment, and the corresponding accounting for
non-cash charges on financial performance. In addition, management
believes non-GAAP financial measures enhance the comparability of results
against prior periods.
-- A reconciliation to the most directly comparable GAAP measure of all
non-GAAP financial measures included in this press release for the three
and nine months ended September 30, 2026, and 2025 are as follows:
(in thousands
except per-share For the three months For the nine months
amounts) ended September 30, ended September 30,
2026 2025 2026 2025
---------- ---------- ----------- -----------
Revenue $1,203 $1,211 $3,932 $3,202
Operating expenses 13,479 12,970 41,122 38,831
Other (Income)
Comments